From the Department of Biochemistry, Osaka University
Graduate School of Medicine, § Department of Internal
Medicine and Molecular Science, Osaka University Graduate School of
Medicine, ** Department of Molecular Therapeutics, Osaka University
Graduate School of Medicine, 2-2 Yamadaoka, Suita,
Osaka 565-0871, Japan, ¶ Department of Biochemistry,
School of Allied Health Science, Osaka University Faculty of
Medicine, and Department of Pathology, School of Allied Health
Science, Osaka University Faculty of Medicine, 1-7 Yamadoaka,
Suita, Osaka 565-0871, Japan
Received for publication, July 26, 2000, and in revised form, September 22, 2000
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The enzyme GnT-III
( The remodeling of cell surface oligosaccharides by
glycosyltransferase gene transfection has led to a better understanding of the biological functions of several glycoproteins (reviewed in Ref.
1). Changes in adhesion molecules and growth factor receptors by
modification of their oligosaccharide structure are associated with the
function and the biological behavior of cancer cells (2-4). These
phenomena appear to be linked to the progression of cancer metastasis
and invasion. However, the mechanism for this is complicated. One of
the likely contributing molecules is the homophilic adhesion molecule,
E-cadherin (5, 6), a decreased expression of which is highly associated
with the initial step of metastasis in certain types of cancer (7-10). E-cadherin contains five consensus N-glycosylation sites.
These N-glycans on E-cadherin can be modified with a
bisecting N-acetylglucosamine (GlcNAc) structure, which is
the product of 1,4-N-acetylglucosaminyltransferase III) catalyzes the
addition of a bisecting N-acetylglucosamine (GlcNAc) residue on glycoproteins. Our previous study described that the transfection of GnT-lll into mouse melanoma cells results in the enhanced expression of E-cadherin, which in turn leads to the suppression of lung metastasis. It has recently been proposed that the
phosphorylation of a tyrosine residue of
-catenin is associated with
cell migration. The present study reports on the importance of
bisecting GlcNAc residues by GnT-lll on tyrosine phosphorylation of
-catenin using three types of cancer cell lines. An addition of
bisecting GlcNAc residues to E-cadherin leads to an alteration in cell
morphology and the localization of
-catenin after epidermal growth
factor stimulation. These changes are the result of a down-regulation
in the tyrosine phosphorylation of
-catenin. In addition, tyrosine
phosphorylation of
-catenin by transfection of constitutively active
c-src was suppressed in GnT-III transfectants as well as in the case of
epidermal growth factor stimulation. Treatment with tunicamycin
abolished any differences in
-catenin phosphorylation for the mock
vis à vis the GnT-lll transfectants. Thus, the
addition of a specific N-glycan structure, the bisecting
GlcNAc to E-cadherin-
-catenin complex, down-regulates the
intracellular signaling pathway, suggesting its implication in cell
motility and the suppression of cancer metastasis.
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1,4-N-acetylglucosaminyltransferase lll
(GnT-III,1 EC 2.4.1.144)
(11). GnT-III catalyzes the attachment of a GlcNAc residue to a
1-4
mannose residue in the core region of N-glycans, as shown in
Fig. 1.
View larger version (16K):
[in a new window]
Fig. 1.
Reaction pathway for the synthesis of
GnT-lll. Man, mannose; UDP-GlcNAc, uridine
5'-diphosphate-N-acetyl-glucosamine; Asn, asparagine; GlcNAc,
N-acetylglucosamine.
In an earlier study, we demonstrated that the bisecting
GlcNAc on E-cadherin suppressed lung metastasis of melanoma
cells (12). However, the mechanism has not been fully investigated. The
function of E-cadherin is also controlled via molecules from the
cytoplasm, namely -,
-, and
-catenins (13, 14). The deletion
or the mutational inactivation of
-catenin leads to the abolition of
E-cadherin activity and tumor invasion (15, 16). Recently, the
biological significance of the tyrosine phosphorylation of
-catenin
has been examined by several groups (17-20). It is possible that this
phosphorylation could disturb E-cadherin/cytoskeleton interactions
(17). During cell migration,
-catenin accumulates in the cytosol in
a free, uncomplexed, and tyrosine-phosphorylated form (19). In
contrast, this type of
-catenin is not observed during the quiescent
phase, suggesting that the tyrosine phosphorylation of
-catenin is
linked to cell migration (20). Thus, increases in
tyrosine-phosphorylated
-catenin are thought to contribute to the
malignant progression and metastasis of tumor cells.
It has been reported that EGF or v-src phosphorylates -catenin in
the case of breast cancer and MDCK cells (21-23). EGF receptor (EGF-R)
is also a glycoprotein, and its sugar chain represents a potential
substrate for GnT-III as well as E-cadherin. Therefore, the tyrosine
phosphorylation of
-catenin could be influenced by both aberrantly
glycosylated EGF-R and E-cadherin. In this study, we report on an
investigation of the effects of oligosaccharide modification by GnT-III
on the tyrosine phosphorylation of
-catenin and cell mobility using
three types of cancer cell lines. Our findings show that the pattern of
-catenin tyrosine phosphorylation as the result of stimulation by
EGF or transfection of constitutively active c-src was dramatically
changed in the case of GnT-III transfectants. Possible mechanisms for
this process are discussed.
![]() |
EXPERIMENTAL PROCEDURES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Materials--
Dulbecco's modified Eagle's medium and RPMI
were obtained from Nikken Biomedical Laboratory (Kyoto, Japan).
Penicillin was obtained from Banyu Corp. (Tokyo, Japan). Kanamycin,
G418, and tunicamycin were obtained from Sigma. LipofectoAMINE reagent
was obtained from Life Technologies, Inc. Effectene transfection
reagent was obtained from Qiagen. Biotinylated
erythroagglutinating phytohemagglutinin (E4-PHA) lectin was
obtained from Honen Corp (Tokyo, Japan). A monoclonal antibody against
human -catenin was obtained from Chemicon International Inc.
(Temecula, CA). A sheep polyclonal antibody against human EGF-R was
obtained from Upstate Biotechnology (Lake Placid, NY). A mouse
monoclonal antibody against human GnT-lll was obtained from Fujirebio
(Hachiohji, Japan). A monoclonal antibody against E-cadherin and a
monoclonal antibody against phosphotyrosine (PY20) were obtained from
Transduction Laboratories (Lexington, KY). A peroxidase-conjugated goat
antibody against mouse lgG was obtained from Promega (Madison, WI). A
peroxidase-conjugated rabbit antibody against sheep IgG was obtained
from Dako (Kyoto, Japan). A detection kit for horseradish
peroxidase-avidin complex (ABC kit) was obtained from Vector
Laboratories (Burlingame, CA). Fluorescein isothiocyanate-labeled goat
antibody against mouse lgG was obtained from Dickinson Immunocytometry
Systems (San Jose, CA). EGF was obtained from Wakunaga (Hiroshima,
Japan). Polyvinylidene difluoride membrane was obtained from Millipore
Corp. (Bedford, MA). A Zeta-probe membrane was obtained from Bio-Rad.
Protein G-Sepharose 4 FF beads and enhanced chemiluminescence system
(ECL) were obtained from Amersham Pharmacia Biotech. Permafluor aqueous
mounting medium was obtained from Immunon. The bicinchoninic acid (BCA)
kit was obtained from Pierce.
Establishment of GnT-lll-transfected B16-hm, Huh7, and WiDr
Cells--
A mouse melanoma cell line, B16-hm was established from
B16-F1 cells as described previously (12). A human colon cancer cell
line, WiDr, was provided by the American Type Culture Collection (Manassas, VA). A human hepatoma cell line, Huh7, was provided by the
Japanese Health Science Foundation (Tokyo, Japan). B16-hm cells were
cultured in Dulbecco's modified Eagle's medium, and Huh7 and WiDr
cells were cultured in RPMI. Each medium contained 100 µg/ml
kanamycin, 50 units/ml penicillin, and 10% fetal calf serum. Cell
lines stably expressing GnT-lll were generated as described previously
(12), and vectors that were used were constructed as follows. A human
GnT-lll cDNA (24) was inserted into a mammalian expression vector,
pCXN, which is regulated by the -actin promoter and has a neo
(G418)-resistant gene (25). Twenty micrograms of this vector was
transfected into Huh7 and WiDr cells with LipofectoAMINE reagent.
Selection was performed via the addition of 600 µg/ml G418. One
positive clone (Huh7-GIII) and one negative clone of Huh7 cells
(Huh7-M) and two positive clones of WiDr cells (WiDr-GT1 and WiDr-GT2)
and two negative clones of WiDr cells (WiDr-M1 and WiDr-M2) were
randomly selected. The GnT-lll transfectants of B16-hm cells had
previously been established by Yoshimura et al. (12).
Assay of GnT-lll and Northern Blot Analysis-- GnT-lll activity of various cells was assayed with high performance liquid chromatography using a fluorescence-labeled sugar chain as a substrate (26), and the expression of GnT-III mRNA was investigated by Northern blot analysis. Total RNA was prepared from various cell lines according to the method reported previously (27). Approximately 20 µg of RNAs were electrophoresed on a 1% agarose gel containing 2.2 M formaldehyde and transferred onto a Zeta-probe membrane by capillary action. Northern blot analysis of GnT-lll was performed as reported previously (28).
Western Blot Analysis-- Twenty micrograms of proteins that had been extracted from mock and GnT-lll transfectants of B16-hm, Huh7, and WiDr cells were electrophoresed on a 8% polyacrylamide gel and then transferred onto a polyvinylidene difluoride membrane. After blocking with phosphate-buffered saline (PBS) containing 3% bovine serum albumin overnight at 4 °C, the membrane filter was incubated with anti-human E-cadherin and anti-EGF-R and diluted with Tris-buffered saline containing 0.05% Tween 20 (TBS-T, 1:1000) for 2 h at room temperature. Each filter was washed 3 times with TBS-T for 10 min each and then incubated with TBS-T containing peroxidase-conjugated goat antibody to mouse lgG for anti-E-cadherin and rabbit antibody to sheep IgG for anti-EGF-R diluted to 1: 2500 with TBS-T for 1 h at room temperature. After the membrane was washed 3 times with TBS-T for 10 min each, it was developed by an ECL according to the manufacturer's recommended protocol.
Lectin Blot Analysis of Immunoprecipitated E-cadherin-- Mock and GnT-lll transfectants of WiDr cells were plated on 10-cm dishes and incubated for 72 h. After washing with PBS, cells were lysed in a lysis buffer (10 mM Tris-HCl, pH 7.8, 0.15 M NaCl, 1 mM EDTA, 0.5% SDS, 0.5% Triton X-100, 2 mM CaCl2, 10% (w/v) glycerol, 1 mM phenylmethanesulfonyl fluoride, 1 µM pepstatin, 10 µg/ml leupeptin, and 10 µg/ml aprotinin) for 30 min on ice and precleared by centrifugation at 15000 rpm for 15 min at 4 °C. For immunoprecipitation, 15 µl of protein G-Sepharose 4FF beads were added to the above supernatant and rotated for 1 h at 4 °C with end-over-end rotations. Protein G-Sepharose 4FF beads were precleared by centrifugation at 3000 rpm for 5 min at 4 °C. After incubation with 1 µg of anti-E-cadherin antibody for 2 h at 4 °C with end-over-end rotations, immune complexes were collected with 15 µl of protein G-Sepharose 4 FF beads. After washing with a lysis buffer 5 times, the complexes were released by boiling in Laemmli sampling buffer, separated by 6% SDS-polyacrylamide gel electrophoresis, and electrotransferred onto a polyvinylidene difluoride membrane. The membrane was blocked in PBS containing 3% bovine serum albumin and incubated for 1 h with E4-PHA lectin (10 µg/ml). E4-PHA lectin binds preferentially to bisecting GlcNAc residues, and the binding of E4-PHA is enhanced by the presence of bisecting GlcNAc structures (29). After washing 3 times with TBS-T for 10 min each, the membrane was incubated with TBS-T containing ABC kit for 1 h. After the membrane was washed 3 times with TBS-T for 10 min each, it was developed by ECL according to the manufacturer's protocol. After submerging in stripping buffer (62.5 mM, Tris-HCl, pH 6.8, 2% SDS, 100 mM 2-mercaptoethanol) at 50 °C for 1 h, the membrane was blocked with PBS containing 3% bovine serum albumin at 4 °C overnight, and then it was subjected to Western blot analysis using an anti-E-cadherin monoclonal antibody as described above.
Cell Migration and Immunofluorescence--
Mock and GnT-III
transfectants of WiDr cells were plated at a density of 1 × 104 cells/cm2 on 6-cm dishes. The mobility of
mock and GnT-III transfectants of WiDr cells after EGF treatment were
continuously observed with an optical microscope Diaphoto 300 (Nikon,
Japan). The intracellular distribution of -catenin in mock and
GnT-III transfectants of WiDr cells was investigated by
photofluorescent immunochemical methods. Briefly, cells were plated at
a density of 1 × 104 cells/cm2 on 8-well
chamber slides, cultured for 48 h, and incubated for 24 h in
RPMI or Dulbecco's modified Eagle's medium containing 2% fetal calf
serum. After treatment with EGF at the indicated time intervals, cells
were washed twice with PBS, fixed with 3% paraformaldehyde in PBS for
20 min at room temperature, blocked, and permeabilized with 1% saponin
and 1% bovine serum albumin in PBS for 20 min at 4 °C. The cells
were incubated with 1/50-diluted anti-
-catenin antibody at room
temperature for 2 h with PBS containing 1% bovine serum albumin
and 1% saponin. Primary antibody binding was detected with a
fluorescein isothiocyanate-labeled goat antibody to mouse lgG for
1 h at room temperature. Coverslips were mounted under a
Permafluor aqueous mounting medium. Stained cells were viewed with a
laser scanning confocal microscope LSM410 (Carl Zeiss, Germany) and
subsequently handled using Adobe Photoshop.
Tyrosine Phosphorylation of -Catenin and EGF-R--
Mock and
GnT-III transfectants of WiDr, B16-hm, and Huh7 cells were plated at a
density of 4 × 104 cells/cm2 on 10-cm
dishes and incubated in normal conditions for 72 h. Those cells,
in a subconfluent state, were further cultured for 24 h in RPMI or
Dulbecco's modified Eagle's medium (Nikken, Kyoto, Japan) containing
2% fetal calf serum and were then treated with 50 ng/ml EGF. After
washing with an ice-cold solution of PBS for the indicated time
intervals, the cells were lysed in an ice-cold lysis buffer (5 mM EDTA, 1 mM sodium orthovanadate, 1 mM sodium pyrophosphate, 100 mM sodium
fluoride, 0.5% Triton X-100, 1 mM phenylmethanesulfonyl
fluoride, 1 µM pepstatin, 10 µg/ml aprotinin, and 10 µg/ml leupeptin) for 30 min on ice and precleared to remove pellets
(insoluble fraction) by centrifugation at 15000 rpm for 15 min at
4 °C. Immunoprecipitation was performed using anti-
-catenin or
anti-EGF-R antibody. Bound proteins were subjected to 6%
SDS-polyacrylamide gel electrophoresis and directed by immunoblotting
with anti-PY20. After reprobing and blocking the membrane, it was
subjected to Western blot analysis using anti-
-catenin or EGF-R as
described above.
Tunicamycin Treatment--
To further investigate the importance
of oligosaccharides on -catenin phosphorylation, cells were treated
with 0.5 µg/ml tunicamycin (Sigma) for 24 h before EGF stimulation.
Tyrosine Phosphorylation of -Catenin by the Transfection of a
Constitutively Active Form of c-src--
The src expression vector,
c-srcY527F, which is regulated by SV40 promoter and constitutively
activated by mutation from 527 tyrosine to phenylalanine, was kindly
provided by Dr. Fukuda (Ikeda City Hospital, Osaka, Japan) (30). This
vector was transfected into mock and GnT-III transfectants of WiDr
cells with Effectene according to the standard protocol. After 48 h, the tyrosine phosphorylation of
-catenin in these cells was
investigated as described above.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Establishment of GnT-lll-transfected WiDr and Huh7
Cells--
Although the GnT-lll activity of WiDr and Huh7 cells was
quite low, WiDr-GT1, -GT2, and Huh7-GIII showed >100 times higher levels of GnT-lll activity than their mock transfectants (Fig. 2). Northern blot analysis showed a high
level of expression of GnT-lll mRNA in GnT-III-transfected WiDr and
Huh7 cells, which is consistent with the observed enzyme activity (Fig.
2A) and suggests that the high levels of GnT-lll activity in
WiDr-GT1, -GT2, and Huh7-Glll were due to the high transcriptional
levels. Western blot analysis showed a high level of GnT-lll protein in GnT-lll transfectants (Fig. 2B). Similar results of GnT-lll
expression were observed in GnT-lll-transfected B16-hm cells
(12).
|
Western Blot and Lectin Blot Analyses of E-cadherin and
EGF-R--
The expression of E-cadherin and EGF-R was investigated by
Western blot analysis. Whereas the expression of E-cadherin in B16-hm
cells was increased in the case of GnT-lll transfectants compared with
mock transfectants (3), the level in the GnT-lll transfectants of WiDr
and Huh7 cells was nearly the same compared with each mock
transfectant. However, the molecular size of E-cadherin in
GnT-lll-transfected WiDr and Huh7 cells was smaller than that in the
mock transfectants, suggesting that an extension of
N-oligosaccharide in E-cadherin had been suppressed by the
action of GnT-lll (Fig. 3A,
upper panel). The level of EGF-R expression was very low in both mock and GnT-lll transfectants of B16-hm cells. In contrast, a
high level of expression of EGF-R was observed in WiDr and Huh7 cells,
and this level was nearly equal in both the mock and the GnT-lll
transfectants. The molecular size of EGF-R in GnT-lll-transfected WiDr
and Huh7 cells was smaller than that of the mock transfectants as well
as in the case of E-cadherin (Fig. 3A, lower
panel).
|
To further investigate the source of the differences in the molecular size of E-cadherin in mock and GnT-lll transfectants, lectin blot analysis on immunoprecipitated E-cadherin was performed using biotinylated E4-PHA. E-cadherin, which had been immunoprecipitated from WiDr-GT1, -GT2, and Huh7-Glll cells exhibited an increase in E4-PHA binding compared with mock transfectants (Fig. 3B, a). An increase in E4-PHA binding to EGF-R immunoprecipitated from GnT-lll transfectants was also observed (Fig. 3B, b). These results indicate that GnT-lll transfection led to an increase in the number of bisecting GlcNAc residues on the N-glycans of E-cadherin and EGF-R in WiDr and Huh7 cells.
Cell Morphology and Distribution of -Catenin after EGF
Treatment--
When the cells were treated with EGF, the degree of
cell-cell contacts became less strong in the mock cells. A typical
pattern of changes in cell morphology was observed in WiDr cells (Fig. 4A). After 60 min, the
morphology of the mock cells returned to the original shape. This
change, however, was negligible in the case of GnT-lll transfectants.
It is interesting to note that the intracellular localization of
-catenin was altered along with the morphological alteration of mock
transfectants (Fig. 4B). The localization of
-catenin was
changed from the cell membrane to the cytoplasm after EGF treatment. In
the GnT-lll transfectants, most of the
-catenin continued to remain
distributed along the entire cell membrane after EGF treatment.
|
Tyrosine Phosphorylation of -Catenin after EGF
Treatment--
Since EGF treatment is a well known method for
stimulating the tyrosine phosphorylation of
-catenin,
GnT-lll-transfected WiDr, B16-hm, and Huh7 cells were treated with 50 ng/ml EGF. As shown in Fig. 5, a dramatic
difference in tyrosine phosphorylation of
-catenin was observed
between GnT-lll and mock transfectants. When EGF was added to
mock-transfected WiDr cells, the tyrosine phosphorylation of
-catenin increased within 15 min of EGF stimulation and persisted
for at least 60 min. In contrast, the levels of tyrosine
phosphorylation of
-catenin were very low and increased only
slightly at 15 min after EGF stimulation and then decreased in the
GnT-III transfectants (Fig. 5A, upper panel). In
the case of B16-hm cells, the basal level of tyrosine phosphorylation
of
-catenin before EGF treatment was somewhat higher than that in the WiDr cells. The tyrosine phosphorylation of
-catenin was slightly increased in mock cells after EGF treatment but was
dramatically decreased in GnT-lll transfectants (Fig. 5B,
upper panel). In the case of Huh7 cells, the tyrosine
phosphorylation of
-catenin was much weaker than the B16-hm and
WiDr cells. However, the difference of
-catenin
phosphorylation between mock and GnT-lll transfectants of Huh7 cells
was also observed. The degree of
-catenin phosphorylation at 30 min
in GnT-lll transfectants was ~70% that of mock transfectant levels
(the mean of 3 experiments; Fig. 5C, upper
panel). Collectively, the tyrosine phosphorylation of
-catenin
increased in mock transfectants of WiDr, B16-hm, and Huh7 cells,
whereas it was suppressed or decreased in GnT-lll transfectants after
EGF treatment.
|
Tyrosine Phosphorylation of EGF-R--
To verify whether or not
GnT-lll transfection led to an alteration in EGF-R function, tyrosine
phosphorylation levels of EGF-R after EGF treatment were investigated.
As shown in Fig. 6, the levels of EGF-R
phosphorylation were dramatically enhanced at 5 min after EGF treatment
in both mock and GnT-lll transfectants of WiDr cells. The time course
pattern of EGF-R phosphorylation in GnT-lll transfectants was quite
similar to that of mock transfectants, suggesting that a similar
signaling via EGF-R was transduced.
|
The Treatment with Tunicamycin--
Tunicamycin inhibits the
N-glycosylation of glycoproteins in higher organisms by
blocking the first step in biosynthesis of the lipid-linked
oligosaccharide precursor. To determine the extent of involvement of
oligosaccharides in -catenin phosphorylation, mock and GnT-lll
transfectants were treated with tunicamycin before the addition of EGF.
As shown in Fig. 7, the pattern of
tyrosine phosphorylation of
-catenin for mock and GnT-lll
transfectants became nearly identical after tunicamycin treatment. This
result suggests a direct involvement of the bisecting GlcNAc residue in
terms of variations in the phosphorylation of
-catenin for mock
vis à vis GnT-lll transfectants. Thus, the inhibition
of N-glycosylation in glycoproteins led to an alteration of
the tyrosine phosphorylation in
-catenin after EGF treatment.
|
The Effect of src Transfection on Tyrosine Phosphorylation of
-Catenin--
To investigate the effect of tyrosine phosphorylation
of
-catenin by other well known alternative pathways, a
constitutively active form of src was transfected into GnT-lll and
mock-transfected WiDr cells. In mock cells, the levels of tyrosine
phosphorylation of
-catenin by src transfection was elevated by more
than five times the levels detected before transfection but was blocked by treatment with tunicamycin. In contrast, in the case of GnT-III transfectants, this elevation of
-catenin phosphorylation by this
active form of src did not occur (Fig. 8,
A and B).
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In many glycoproteins, particularly adhesion molecules and growth
factor receptors on cell surfaces, N-linked oligosaccharides contribute to the folding, stability, and biological functions of the
molecules (31-33). Our results indicate that the overexpression of
GnT-III could lead to the modification of the tyrosine phosphorylation pattern of -catenin after EGF stimulation. Previous studies from our
laboratory have demonstrated that the amount of E-cadherin expression
was increased in GnT-III-transfected mouse melanoma B16-hm cells, due
to delayed turn-over, compared with mock transfectants (3). Increases
in E-cadherin levels on the cell surface enhanced cell-cell contacts
and aggregations.
However, in human cancer cells such as WiDr and Huh7, the expression of
E-cadherin in GnT-III transfectants was equivalent to that of mock
transfectants, although the oligosaccharide structures of E-cadherin
were altered. Although morphological alteration such as compact
organization was observed in GnT-III-transfected B16-hm cells, it was
not observed in the cases of WiDr and Huh7 cells. These results suggest
that proteases, which contribute to the cleavage of E-cadherin, are
different between humans and mice. In contrast, both E4-PHA binding and
the molecular size of EGF-R in these transfectants were changed, but
the tyrosine phosphorylation of EGF-R on GnT-III transfectants was
observed to occur normally both in WiDr and Huh7 cells. Therefore,
changes in the tyrosine phosphorylation of -catenin are not due to
EGF-R dysfunction but, rather, its induction by other factors such
as downstream signals of EGF-R.
We next examined changes in the integrity of cell-cell contacts between
mock and GnT-III-transfected WiDr cells that had been treated with EGF.
The GnT-III transfectants of WiDr cells barely changed in terms of cell
morphology and cell-cell contact after EGF stimulation. Interestingly,
changes in the cell-cell contacts of mock cells were consistent with
the tyrosine phosphorylation pattern of -catenin. To further explore
the relationship between cell-cell adhesion and tyrosine
phosphorylation of
-catenin, the localization of
-catenin in mock
and GnT-III transfectants of WiDr cells was investigated via an
immunofluorescence method. The localization of
-catenin in mock
transfectants was redistributed from the lineage of cell membrane to
cytoplasm after EGF treatment. In contrast, the localization of
-catenin in GnT-III transfectants remained along the cell-cell
contact region of adjacent-adhering cells after EGF treatment. Thus,
the nature of cell-cell contacts for the GnT-III-transfected WiDr cells
remained unchanged after EGF stimulation.
An alteration in cadherin-mediated cell-cell adhesion is frequently
associated with the tyrosine phosphorylation of -catenin. This
phosphorylation is thought to be caused by the Src family of tyrosine
kinases and receptors with tyrosine kinase activity such as growth
factors like EGF, hepatocyte growth factor, platelet-derived growth
factor, and colony stimulating factor-1. In this study, EGF stimulation
and src transfection were used to phosphorylate
-catenin. The
tyrosine phosphorylation of
-catenin after EGF treatment was
suppressed in GnT-III transfectants of three types of cancer cells.
Changes in the phosphorylation pattern were a little different in
B16-hm cells. A basal level of
-catenin phosphorylation was higher
in B16-hm cells than WiDr cell and Huh7 cells. It might be due to
metastatic potential of melanoma cells in terms of migration. In the
case of Huh7 cells, tyrosine phosphorylation of
-catenin after EGF
treatment was quite low and suppressed in GnT-III transfectants at 70%
levels. This might be due to low potentials of cell migration in Huh7
cells. Since the modification of EGF-R oligosaccharide by GnT-III does
not involve changes in the tyrosine phosphorylation of
-catenin,
another possibility for the suppression of tyrosine phosphorylation of
-catenin involves complex formation between
-catenin and
aberrantly glycosylated E-cadherin. Conformational changes of this
complex might inhibit the action of kinases for
-catenin. To further
investigate this, we examined the effect of transfection of activated
src into GnT-III transfectants. As expected, tyrosine phosphorylation
of
-catenin by the src transfectant was dramatically suppressed in
GnT-III transfectants as well as in the case of EGF stimulation (Fig.
8). In addition, to ensure the involvement of changes in the
N-linked oligosaccharides structure, cells were treated with
tunicamycin, which inhibits the N-glycosylation of
glycoproteins by blocking the first step in the biosynthesis of a
lipid-linked oligosaccharide precursor. The tyrosine phosphorylation of
-catenin in tunicamycin-treated mock transfectants was nearly identical to that of GnT-III transfectants, suggesting that changes in
N-glycosylation directly affect the tyrosine phosphorylation of
-catenin. Levels of E-cadherin were increased in GnT-III
transfectants of B16-hm cells but remained unchanged in GnT-III
transfectants of WiDr and Huh7 cells. Nevertheless, the tyrosine
phosphorylation of
-catenin was suppressed in all GnT-III
transfectants, suggesting that aberrant glycosylated E-cadherin is not
involved in cell-cell contacts. In fact, it has been reported that
E-cadherin oligosaccharides are not important for their function as an
adhesion molecule (34). However, the present study indicates that
bisecting GlcNAc residues on E-cadherin affect intracellular signaling,
such as
-catenin phosphorylation, which might be due to an
alteration in the E-cadherin-catenin complex. The up-regulation of src
or EGF signaling occurs during the progression of cancer (35). If the
action of src or EGF to phosphorylate
-catenin is inhibited by
GnT-III in vivo, GnT-III contributes to the progression of
cancer in multi-steps. In summary, the addition of bisecting GlcNAc
residues of E-cadherin-
-catenin by GnT-III down-regulates the
tyrosine phosphorylation of
-catenin, which might lead to the
suppression of tumor progression such as invasion or metastasis.
![]() |
FOOTNOTES |
---|
* This work was supported in part by a Grant-in-aid for Scientific Research on Priority Areas 10178104 from the Ministry of Education, Science, Sports, and Culture of Japan.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.:
81-6-6879-3420; Fax: 81-6-6879-3429; E-mail:
proftani@biochem.med.osaka- u.ac.jp.
Published, JBC Papers in Press, October 9, 2000, DOI 10.1074/jbc.M006689200
![]() |
ABBREVIATIONS |
---|
The abbreviations used are:
GnT-lll, -mannoside
-1,4-N acetylglucosaminyltransferase lll;
GlcNAc, N-acetylglucosamine;
EGF-R, epidermal growth factor
receptor;
PBS, phosphate-buffered-saline;
TBS-T, Tris-buffered saline
containing 0.05% Tween 20;
E4-PHA, erythroagglutinating
phytohemagglutinin.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Taniguchi, N., Yoshimura, M., Miyoshi, E., Ihara, Y., Nishikawa, A., and Fujii, S. (1996) Glycobiology 6, 691-694[Medline] [Order article via Infotrieve] |
2. | Dwek, R. A., Christopher, J. E., David, J. H., and Mark, R. W. (1993) Annu. Rev. Biochem. 62, 65-100[CrossRef][Medline] [Order article via Infotrieve] |
3. |
Yoshimura, M.,
Ihara, Y.,
Matsuzawa, Y.,
and Taniguchi, N.
(1996)
J. Biol. Chem.
271,
13811-13815 |
4. |
Tsuda, T.,
Ikeda, Y.,
and Taniguchi, N. (1994)
(2000)
J. Biol. Chem.
275,
21988-21982 |
5. | Takeichi, M. (1991) Science 251, 1451-1455[Medline] [Order article via Infotrieve] |
6. | Vleminckx, K., Vakaet, L. J., Mareel, M., Fiers, W., and Van Roy, F. (1991) Cell 66, 107-119[Medline] [Order article via Infotrieve] |
7. | Frixen, U. H., Behrens, J., Sachs, M., Eberle, G., Voss, B., Warda, A., Lochner, D., and Birchmeier, W. (1991) J. Cell Biol. 113, 173-185[Abstract] |
8. | Umbas, R., Schalken, J. A., Aalders, T. W., Carter, B. S., Karthaus, H. F. M., Schaafsma, H, E., Debruyne, F. M. J., and Isaacs, W. B. (1992) Cancer Res. 52, 5104-5109[Abstract] |
9. | Mayer, B., Johnson, J. P., Leitl, F., Jauch, K. W., Heiss, M. M., Schildberg, F. W., Birchmeier, W., and Funke, I. (1993) Cancer Res. 53, 1690-1695[Abstract] |
10. | Dorudi, S., Sheffield, J. P., Poulsom, R., Northover, J. M. A., and Hart, I. R. (1993) Am. J. Pathol. 142, 981-986[Abstract] |
11. |
Narasimham, S.
(1982)
J. Biol. Chem.
257,
10235-10242 |
12. | Yoshimura, M., Nishikawa, A., Ihara, Y., Taniguchi, S., and Taniguchi, N. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 8754-8758[Abstract] |
13. | Nagafuchi, A., and Takeichi, M. (1988) EMBO J. 7, 3679-3684[Abstract] |
14. | Ozawa, M., Baribabault, H., and Kemler, R. (1989) EMBO J. 8, 1711-1717[Abstract] |
15. | Oyama, T., Kanai, Y., Ochiai, A., Akimoto, S., Oda, T., Yanagihara, K., Nagafuchi, A., Tsukita, S., Shibamoto, S., Ito, F., Takeichi, M., Matsuda, H., and Hirohashi, S. (1994) Cancer Res. 54, 6282-6287[Abstract] |
16. | Kawanishi, J., Kato, J., Sasaki, K., Fujii, S., Watanabe, N., and Niitsu, Y. (1995) Mol. Cell. Biol. 15, 1175-1181[Abstract] |
17. | Behrens, J., Vakaet, L., Friis, R., Winterhager, E., Roy, F. V., Mareel, M. M., and Birchmeier, W. (1993) J. Cell Biol. 120, 757-766[Abstract] |
18. | Sommers, C. L., Gelmann, E. P., Kemler, R., Cowin, P., and Byers, S. W. (1994) Cancer Res. 54, 3544-3552[Abstract] |
19. |
Müller, T.,
Choidas, A.,
Reichmann, E.,
and Ullrich, A.
(1999)
J. Biol. Chem.
274,
10173-10183 |
20. | Takahashi, K., Suzuki, K., and Tsukatani, Y. (1997) Oncogene 15, 71-78[CrossRef][Medline] [Order article via Infotrieve] |
21. | Hamaguchi, M., Matsuyoshi, N., Ohnishi, Y., Gotoh, B., Takeichi, M., and Nagai, Y. (1993) EMBO J. 12, 307-314[Abstract] |
22. | Hoschuetzky, H., Aberle, H., and Kemler, R. (1994) J. Cell Biol. 127, 1375-1380[Abstract] |
23. |
Hazan, R. B.,
and Norton, L.
(1998)
J. Biol. Chem.
273,
9078-9084 |
24. | Ihara, Y., Nishikawa, A., Tohma, T., Soejima, M., Niikawa, N., and Taniguchi, N. (1993) J. Biochem. (Tokyo) 113, 692-698[Abstract] |
25. | Niwa, H., Yamamura, K., and Miyazaki, J. (1991) Gene 108, 193-200[CrossRef][Medline] [Order article via Infotrieve] |
26. | Taniguchi, N., Nishikawa, A., Fujii, S., and Gu, J. (1989) Methods Enzymol. 179, 397-408[Medline] [Order article via Infotrieve] |
27. | Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-159[CrossRef][Medline] [Order article via Infotrieve] |
28. | Miyoshi, E., Nishikawa, A., Ihara, Y., Gu, J., Sugiyama, T., Hayashi, N., Fusamoto, H., Kamada, T., and Taniguchi, N. (1993) Cancer Res. 53, 3899-3902[Abstract] |
29. |
Yamashita, K.,
Hitoi, A,
and Kobata, A.
(1983)
J. Biol. Chem.
258,
14753-14755 |
30. | Nada, S., Okada, M., MacAuley, A., Cooper, J. A., and Nakagawa, H. (1991) Nature 351, 69-72[CrossRef][Medline] [Order article via Infotrieve] |
31. | Hakomori, S-I. (1989) Adv. Cancer Res. 52, 257-331[Medline] [Order article via Infotrieve] |
32. | Dwek, R. A. (1995) Science 269, 1234-1235[Medline] [Order article via Infotrieve] |
33. | Wyss, D. F., Choi, J. S., Li, J., Knoppers, M. H., Willis, K. J., Arulanandam, A. R. N., Smolyar, A., Reinherz, E. L., and Wagner, G. (1995) Science 269, 1273-1278[Medline] [Order article via Infotrieve] |
34. | Shirahashi, Y., Nose, A., Iwasaki, K., and Takeichi, M. (1986) Cell Struct. Funct. 11, 245-252[Medline] [Order article via Infotrieve] |
35. | Biscardi, J. S., Tice, D. A., and Parsons, S. J. (1999) Adv. Cancer Res. 76, 61-119[Medline] [Order article via Infotrieve] |